AstraZeneca's TAGRISSO Achieves 8-Year Survival Milestone In Early-Stage EGFR- Mutated Lung Cancer

Submitted by Anonymous on

BioTech AZN AstraZeneca's TAGRISSO Achieves 8-Year Survival Milestone In Early-Stage EGFR- Mutated Lung Cancer September 14, 2026 - 05:15 am EDT Written by RTTNews.com for RTTNews linkedin facebook x email reddit (RTTNews) - AstraZeneca's (AZN) TAGRISSO (osimertinib) delivered an unprecedented...

Case Report: Dramatic response of trastuzumab rezetecan in an NSCLC patient with EGFR sensitive mutation and primary ERBB2 genetic alterations

Submitted by Anonymous on

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have provided significant clinical benefit to patients with EGFR-mutant non-small cel 1 Introduction Lung cancer remains the leading cause of cancer-related death worldwide (1), and non-small cell lung cancer (NSCLC) accounts for...

Early cranial radiotherapy may improve outcomes for patients with EGFR-mutant NSCLC and limited brain metastases

Submitted by Anonymous on

Credit: Unsplash/CC0 Public Domain Early cranial stereotactic radiotherapy (SRT) administered with first-line osimertinib was associated with improved intracranial control and survival outcomes in patients with EGFR-mutant non-small cell lung cancer (NSCLC) and limited brain metastases, according to research presented at...

Johnson & Johnson (JNJ) Reports Lower Side Effects In Advanced EGFR Lung Cancer

Submitted by Anonymous on

Johnson & Johnson (NYSE: JNJ) reported new COPERNICUS Phase 2b data on subcutaneous RYBREVANT FASPRO plus LAZCLUZE in advanced EGFR-mutated NSCLC. The regimen showed reduced treatment-related adverse events compared with existing options, according to the latest study update. Patients in...

BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at...

Submitted by Anonymous on

SAN DIEGO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced updated data from...

Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy

Submitted by Anonymous on

TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, met all prespecified endpoints, including unprecedented placebo-adjusted estimated glomerular filtration rate (eGFR) and composite kidney disease progression benefits.Favorable safety profile, and generally comparable to placebo. Strong commercial launch momentum with...

Subscribe to Newsfeed